Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

600 cancer patients to help unlock secrets of immunotherapy

NCT ID NCT07427186

First seen Feb 26, 2026 · Last updated May 24, 2026 · Updated 14 times

Summary

This study will follow 600 people with early-stage solid cancers (like lung, head and neck, melanoma, or bladder cancer) who receive immunotherapy before surgery. Researchers will collect blood and tumor samples to find biological markers that show whether the treatment is working. The goal is to better understand why some patients respond well to immunotherapy and others do not, which could improve future treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID CANCERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chu Rangueil

    Toulouse, 31400, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hopital Larrey

    Toulouse, 31400, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institut Universitaire Du Cancer de Toulouse - Oncopole

    Toulouse, 31059, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.